# CONNEXT Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/connext-co

- Industry: Biotechnology
- Headquarters: Daegu, South Korea
- Website: www.connext.co.kr
- Total disclosed funding: $17M
- Latest round: Series C (Mar 16, 2026)
- Investors on record: 7

## About

Based in Daegu, South Korea, and founded in 2017, Connext Co., Ltd. operates as a clinical-stage biotech company that focused on developing biological therapeutics. In March 2026, CONNEXT Co., Ltd. raised KRW 15 billion in series C funding from new investors PharmaResearch, Premier Partners, Murex Partners, Soo Investment Capital, and The Next Lab. Returning investor ES Investor also participated in this round. As of May 2023, the company is led by its CEO Lee Woo-jong. 

Connext Co., Ltd. product portfolio includes medicinal recombinant protein products with a primary focus on two technologies: recombinant TLR5 agonist includes CNT101, and CNT102, therapeutic agents designed to prevent side effects associated with radiation and chemotherapy; and recombinant collagenase such as CNT201, and CNT202 designed for the treatment of Peyronie's disease, cellulite, and wound debridement.

The company will use the March 2026 funding to launch an open innovation strategy with PharmaResearch and combine its recombinant protein technology.

## Funding rounds

- Series C, Mar 16, 2026, $10M — Premier Partners, ES Investor, Murex Partners, Soo Investment Capital, The Next Lab, PharmaResearch
- Series A, Oct 31, 2019, $6.7M — KB Investment

## Investors

- KB Investment (https://capitalatlas.ai/funds/kb-investment) — Series A
- Premier Partners (https://capitalatlas.ai/funds/premier-partners) — Series C
- ES Investor (https://capitalatlas.ai/funds/es-investor) — Series C
- Murex Partners (https://capitalatlas.ai/funds/murex-partners) — Series C
- Soo Investment Capital (https://capitalatlas.ai/funds/soo-investment-capital) — Series C
- The Next Lab — Series C
- PharmaResearch — Series C